Suppr超能文献

P2Y1 受体的激活可诱导前列腺癌细胞凋亡并抑制其增殖。

Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA.

出版信息

Biochem Pharmacol. 2011 Aug 15;82(4):418-25. doi: 10.1016/j.bcp.2011.05.013. Epub 2011 May 23.

Abstract

G protein-coupled receptors, the largest cell surface receptor family, have emerged as critical players in cell death and survival. High gene expression level of the G(q)-coupled P2Y(1) nucleotide receptor in PC-3 prostate cancer cells was demonstrated using real-time quantitative PCR and confirmed by Western blotting and confocal laser scanning microscopy. A selective P2Y(1) receptor agonist, the ADP analogue MRS2365, concentration-dependently induced intracellular calcium mobilization (EC(50) 5.28nM), which was diminished by P2Y(1) receptor-selective antagonist MRS2500. P2Y(1) receptor activation by MRS2365 induced apoptosis in assays of Caspase-3, LDH release, and annexin-V staining. The pro-apoptotic effect of MRS2365 was blocked by MRS2500, P2Y(1) siRNA, and an inhibitor of the MAP kinase pathway PD98059. MRS2365 significantly inhibited the proliferation of PC-3 cells, examined using a MTT assay. Thus, activation of the P2Y(1) receptor induced cell death and inhibited growth of human prostatic carcinoma PC-3 cells. Activation of the P2Y(1) receptor should be a novel and promising therapeutic strategy for prostate cancer.

摘要

G 蛋白偶联受体是细胞表面受体家族中最大的家族,已成为细胞死亡和存活的关键参与者。使用实时定量 PCR 证明了 PC-3 前列腺癌细胞中 G(q)偶联 P2Y(1)核苷酸受体的高基因表达水平,并通过 Western blot 和共聚焦激光扫描显微镜得到证实。选择性 P2Y(1)受体激动剂,ADP 类似物 MRS2365,浓度依赖性地诱导细胞内钙动员(EC(50) 5.28nM),该作用被 P2Y(1)受体选择性拮抗剂 MRS2500 减弱。MRS2365 激活 P2Y(1)受体可诱导 Caspase-3、LDH 释放和 Annexin-V 染色检测到的细胞凋亡。MRS2365 的促凋亡作用被 MRS2500、P2Y(1)siRNA 和 MAP 激酶途径抑制剂 PD98059 阻断。MRS2365 显著抑制了 MTT 测定法检测到的 PC-3 细胞的增殖。因此,P2Y(1)受体的激活诱导了人前列腺癌细胞的死亡和抑制生长。激活 P2Y(1)受体应该是前列腺癌的一种新的有前途的治疗策略。

相似文献

引用本文的文献

4
The P2 purinoceptors in prostate cancer.前列腺癌中的 P2 嘌呤能受体。
Purinergic Signal. 2023 Mar;19(1):255-263. doi: 10.1007/s11302-022-09874-2. Epub 2022 Jun 30.
5
P2 purinergic receptor dysregulation in urologic disease.P2 嘌呤能受体失调与泌尿系统疾病。
Purinergic Signal. 2022 Sep;18(3):267-287. doi: 10.1007/s11302-022-09875-1. Epub 2022 Jun 10.

本文引用的文献

6
Extracellular adenosine triphosphate and adenosine in cancer.细胞外三磷酸腺苷和腺苷在癌症中的作用。
Oncogene. 2010 Sep 30;29(39):5346-58. doi: 10.1038/onc.2010.292. Epub 2010 Jul 26.
7
P2Y nucleotide receptors: promise of therapeutic applications.P2Y 核苷酸受体:治疗应用的前景。
Drug Discov Today. 2010 Jul;15(13-14):570-8. doi: 10.1016/j.drudis.2010.05.011. Epub 2010 Jun 2.
9
ADP receptor P2Y(13) induce apoptosis in pancreatic beta-cells.ADP 受体 P2Y(13)诱导胰岛β细胞凋亡。
Cell Mol Life Sci. 2010 Feb;67(3):445-53. doi: 10.1007/s00018-009-0191-3. Epub 2009 Nov 14.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验